Companies · REPL · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc. (REPL)

Every material event, decoded in plain English — what each one means for the stock.

Aug 14, 2026Miss

The approval is old news; now the launch bill starts showing up

Replimune secures $140.5 million, but adds meaningful dilution

FDA approval clears the commercial path, but confirmatory risk remains

Open live on AllSight — the whole market, decoded →